INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,422,888 | -16.7% | 948,798 | +1.2% | 0.01% | -9.1% |
| Q2 2023 | $59,361,740 | +19.5% | 937,488 | +2.2% | 0.01% | +10.0% |
| Q1 2023 | $49,681,434 | +0.5% | 917,478 | -1.7% | 0.01% | 0.0% |
| Q4 2022 | $49,414,632 | +14.0% | 933,761 | +0.3% | 0.01% | 0.0% |
| Q3 2022 | $43,331,000 | -18.9% | 931,263 | -0.5% | 0.01% | -9.1% |
| Q2 2022 | $53,402,000 | -0.1% | 935,572 | +7.0% | 0.01% | +22.2% |
| Q1 2022 | $53,479,000 | +25.7% | 873,978 | +7.6% | 0.01% | +28.6% |
| Q4 2021 | $42,531,000 | +37.7% | 812,586 | -2.0% | 0.01% | +40.0% |
| Q3 2021 | $30,897,000 | -11.7% | 828,797 | -3.4% | 0.01% | -16.7% |
| Q2 2021 | $35,010,000 | +25.1% | 857,660 | +4.0% | 0.01% | +20.0% |
| Q1 2021 | $27,984,000 | -7.8% | 824,748 | -13.6% | 0.01% | -16.7% |
| Q4 2020 | $30,354,000 | +21.9% | 954,551 | -1.7% | 0.01% | +20.0% |
| Q3 2020 | $24,906,000 | +9.4% | 970,615 | +9.5% | 0.01% | 0.0% |
| Q2 2020 | $22,757,000 | +118.6% | 886,518 | +30.9% | 0.01% | +66.7% |
| Q1 2020 | $10,411,000 | -46.8% | 677,473 | +18.8% | 0.00% | -25.0% |
| Q4 2019 | $19,568,000 | +345.4% | 570,348 | -3.0% | 0.00% | +300.0% |
| Q3 2019 | $4,393,000 | -39.6% | 588,177 | +4.9% | 0.00% | -50.0% |
| Q2 2019 | $7,277,000 | +8.2% | 560,601 | +1.6% | 0.00% | 0.0% |
| Q1 2019 | $6,725,000 | +7.7% | 552,037 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $6,247,000 | -48.0% | 548,507 | -1.0% | 0.00% | -33.3% |
| Q3 2018 | $12,019,000 | +26.0% | 553,879 | +2.6% | 0.00% | +50.0% |
| Q2 2018 | $9,542,000 | -8.2% | 540,016 | +9.4% | 0.00% | -33.3% |
| Q1 2018 | $10,390,000 | +47.6% | 493,563 | +1.6% | 0.00% | +50.0% |
| Q4 2017 | $7,038,000 | +10.5% | 485,965 | +20.3% | 0.00% | 0.0% |
| Q3 2017 | $6,372,000 | +30.4% | 403,825 | +2.7% | 0.00% | +100.0% |
| Q2 2017 | $4,886,000 | -27.2% | 393,385 | -4.7% | 0.00% | -50.0% |
| Q1 2017 | $6,710,000 | +9.3% | 412,864 | +1.5% | 0.00% | 0.0% |
| Q4 2016 | $6,137,000 | +2.0% | 406,619 | +3.0% | 0.00% | 0.0% |
| Q3 2016 | $6,014,000 | -60.5% | 394,617 | +0.5% | 0.00% | -60.0% |
| Q2 2016 | $15,236,000 | +68.9% | 392,471 | +22.6% | 0.01% | +66.7% |
| Q1 2016 | $9,019,000 | -47.0% | 320,115 | +1.2% | 0.00% | -50.0% |
| Q4 2015 | $17,022,000 | +69.0% | 316,448 | +25.8% | 0.01% | +100.0% |
| Q3 2015 | $10,071,000 | +34.9% | 251,537 | +7.7% | 0.00% | +50.0% |
| Q2 2015 | $7,463,000 | +51.6% | 233,588 | +13.3% | 0.00% | +100.0% |
| Q1 2015 | $4,922,000 | +55.7% | 206,149 | +15.1% | 0.00% | 0.0% |
| Q4 2014 | $3,162,000 | +24.6% | 179,147 | -3.2% | 0.00% | 0.0% |
| Q3 2014 | $2,537,000 | +241.5% | 185,043 | +319.6% | 0.00% | – |
| Q2 2014 | $743,000 | +98.1% | 44,099 | +114.0% | 0.00% | – |
| Q1 2014 | $375,000 | – | 20,608 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |